Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease (KARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01004575
Recruitment Status : Unknown
Verified September 2015 by Terumo Europe N.V..
Recruitment status was:  Active, not recruiting
First Posted : October 30, 2009
Last Update Posted : September 14, 2015
Information provided by (Responsible Party):
Terumo Europe N.V.

October 29, 2009
October 30, 2009
September 14, 2015
October 2009
July 2011   (Final data collection date for primary outcome measure)
Freedom from Target vessel failure TVF defined as composite of clinically driven target vessel revascularization (TVR)myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel. [ Time Frame: 6 months post-procedure ]
Same as current
Complete list of historical versions of study NCT01004575 on Archive Site
  • Freedom from TVF for patients treated with ≥ 3 mm stents. [ Time Frame: 6 months post-procedure ]
  • Freedom from TVF for patients treated with 2.5 and 2.75 mm stents [ Time Frame: 6 months post-procedure ]
  • Freedom from TVF [ Time Frame: 30 days,12 months and 3 and 5 years post-procedure ]
  • Clinically driven target lesion revascularization (TLR) free rate . [ Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure ]
  • Clinically driven target vessel revascularization (TVR) free rate. [ Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure ]
  • Device success defined as achievement of a residual diameter stenosis of < 50% by QCA or < 30% by visual estimate, using the assigned device only. [ Time Frame: Baseline procedure ]
  • Lesion success defined as the attainment of residual diameter stenosis of < 50% by QCA or < 30% by visual estimate, using any percutaneous method. [ Time Frame: Baseline procedure ]
  • Procedure success defined as achievement of a final diameter stenosis of < 50% by QCA or < 30% by visual estimate, using any percutaneous method, without MACE (composite of cardiac death, MI and TLR) . [ Time Frame: During baseline hospital stay ]
  • Angiographic in-stent acute gain [ Time Frame: Baseline procedure ]
  • Angiographic in-stent and in-segment binary restenosis rate (≥ 50%) diameter stenosis [ Time Frame: 6 months post-procedure ]
  • Angiographic in-stent, in-segment, proximal, and distal minimum lumen diameter (MLD) [ Time Frame: 6 months post-procedure ]
  • In-stent late-loss (as measured by QCA) defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up MLD. [ Time Frame: 6 months post-procedure ]
  • % Diameter Stenosis, in-stent and in-segment . [ Time Frame: 6 months post-procedure ]
  • Neointimal hyperplasia volume as measured by intravascular ultrasound. [ Time Frame: 6 months post-procedure ]
  • Major adverse cardiac events (MACEs) rate . [ Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure ]
  • Serious adverse event rate . [ Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure ]
  • Any device failure . [ Time Frame: Baseline procedure ]
Same as current
Not Provided
Not Provided
Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease
Clinical Evaluation of Kaname Cobalt-Chromium Coronary Stent System in the Treatment of Patients With Coronary Artery Disease
The purpose of this study is to assess whether the new Kaname coronary stent is safe and effective for the treatment of patients with coronary artery disease.

Current treatments for coronary artery disease include conservative treatment (drug therapies) and invasive techniques that help increase blood flow to ischemic or oxygen-deprived regions of the heart. Among the invasive techniques the most frequently used are coronary artery bypass graft surgery (CABG), and percutaneous transluminal coronary angioplasty (PTCA) without or with stents (bare metal stents (BMS) or drug eluting stents (DES)) implantation. However, all of those treatments have limitations and their effectiveness is diminished under certain circumstances. Therefore, it is essential to tailor therapy for each individual patient considering the overall patient's condition, disease severity and progression as well as concomitant diseases. The question of selection of appropriate stent for each individual patient is still unresolved and most of the physicians either follow international or national guidelines or scientific wisdom.

Although the efficacy of DES is undisputable in restenosis prevention, because some patients could have adverse outcomes from a DES, they should be used selectively in those who are most likely to benefit, and in that decision process several important issues should be addressed such as:Patients' adherence to post-stenting therapy, Bleeding risk, Need for elective surgery, Risk for restenosis, Risk for stent thrombosis. It is still believed that many patients will do well with BMSs and that this technology requires further refinements to improve outcome. For the above reasons Terumo has designed the new coronary BMS, Kaname™, a balloon expandable Cobalt-Chromium (CoCr) stent pre-mounted onto a high pressure, semi-compliant balloon on a rapid exchange delivery catheter. The Kaname stent is the subject of the current prospective, multi-centre KARE study.

Phase 2
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Coronary Artery Disease
  • Angioplasty, Transluminal, Percutaneous Coronary
Device: Kaname cobalt-chromium coronary stent
implantation of Kaname Cobalt-Chromium coronary stent
Other Names:
  • Kaname
  • Cobalt-chromium
  • coronary stent
Experimental: Kaname
patients treated with Kaname stent
Intervention: Device: Kaname cobalt-chromium coronary stent
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
August 2016
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is ≥ 18 years old.
  • Patient is eligible for PCI and acceptable candidate for CABG.
  • Clinical evidence of ischemic heart disease and/or a positive functional study. Documented stable angina pectoris (CCS 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia.
  • The target lesion or target vessel meets all the following criteria;a) is a single de novo lesion or restenotic post-PTCA (non-stented) lesion in one native coronary artery.b)The stenosis of target lesion is ≥ 50% and < 100% c)The target lesion length must be ≤ 25 mm d)The target reference vessel diameter must be suitable for treatment with stents between 2.5 and 4.0 mm long
  • Patient has been informed of the nature of the study, understands the study requirements and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.
  • The patient is able to comply with all specified follow-up evaluations.

Exclusion Criteria:

  • Most recent LVEF of the patient is < 25%.
  • Known allergies to the following: aspirin, Clopidogrel bisulfate, Prasugrel or Ticlopidine, heparin, cobalt, chromium, nickel, or contrast agent (that cannot be adequately premedicated).
  • A platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
  • WBC count < 3500 cells/mm3.
  • Evidence of MI with positive Troponin within 72 hours of the intended treatment.
  • Previous PCI (<30 days) anywhere within the target vessel.
  • Planned interventional treatment of any non-target vessel <30 days post-procedure will be required. Planned intervention on the target vessel or on a significant lesion of > 50% stenosis anywhere within the target vessel after the index procedure will be required.
  • The target lesion requires treatment with a device other than PTCA balloon prior to stent placement. (e.g. but not limited to directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).
  • Previous stenting anywhere within the target vessel.
  • Target vessel has evidence of thrombus.
  • Excessive tortuousity (> 60°) of the target vessel proximal to the target lesion (visual estimate).
  • Either of the following characteristics in the target lesion (visual estimate): a)Ostial target lesion or bifurcation lesion b)Target lesion involves a side branch > 2mm in diameter c) Target lesion has excessive tortuousity (> 45°)d)Moderate to severely calcified lesion which can not be successfully predilated e)Target lesion is located in or supplied by an arterial or venous bypass graft f)Significant (> 40%) stenosis proximal or distal to the target lesion. g) A complete occlusion (TIMI flow 0 or 1).
  • Target lesion located in left main trunk.
  • Stroke or transient ischemic attack < prior 180 days.
  • Active peptic ulcer or upper GI bleeding < prior 180 days.
  • The patient has bleeding hemorrhagic diathesis or coagulopathy. The patient will refuse a blood transfusion.
  • The patient has a widespread peripheral vascular disease.
  • Acute or chronic renal dysfunction (creatinine > 2.0 mg/dl).
  • The patient requires multiple stent implantations for a tandem lesion.
  • Life expectancy < 1 year.
  • Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials.
  • In the investigators opinion patient has a co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
  • Patient is in cardiogenic shock.
  • Female of child-bearing potential.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
France,   Germany,   Italy,   Serbia,   Spain
Not Provided
Not Provided
Terumo Europe N.V.
Terumo Europe N.V.
Not Provided
Principal Investigator: Didier Carrie, Prof Dr CHU Rangeuil, 31059 Toulouse, France
Terumo Europe N.V.
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP